Table 1. Clinical and immunological characteristics on patients with ALL included in the study.
| Characteristics | Patient #1 | Patient #2 | Patient #3 |
|---|---|---|---|
| Sex | F | F | F |
| Age at diagnosis (months) | 20 | 104 | 1.5 |
| Le (x 109/L) | 72 | 315 | 430 |
| % of leukemic blasts | >80 | > 85 | > 90 |
| Immunological phenotype | B | T | B |
| Cell surface molecules | CD10+ CD19+ CD22+ CD24+ CD38+ CD79a+ |
CD3+ CD5+ CD7+ CD10+ CD34+ CD38+ |
CD10- CD19+ CD22+ CD34+ CD36+ CD79a+ |
| Cytogenetic | normal | normal | MLL/AF4+; t (4;11)+ |
| MRD at day 35 | - | < 0.5% | - |
| Chemotherapy(sensitivity) | + | + | - |
Le: leukocytes numbers; ALL: acute lymphoblastic leukemia; MRD: minimal residual disease.